Salvage therapy with 2-chlorodeoxyadenosine for refractory and relapsed pediatric Langerhans cell histiocytosis: an updated nationwide survey in Japan

被引：0

作者：

Maki Taniguchi

Kenichi Sakamoto

Yoko Shioda

Takehiko Doi

Ko Kudo

Hisanori Fujino

Kazuko Kudo

Akira Morimoto

机构：

[1] Hiroshima University Graduate School of Biomedical and Health Sciences,Department of Pediatrics

[2] National Center for Child Health and Development,Children’s Cancer Center

[3] Hirosaki University Graduate School of Medicine,Department of Pediatrics

[4] Osaka Red Cross Hospital,Department of Pediatrics

[5] Fujita Health University,Department of Pediatrics

[6] Jichi Medical University School of Medicine,Department of Pediatrics

来源：

International Journal of Hematology | 2021年 / 113卷

关键词：

Langerhans cell histiocytosis; 2-chlorodeoxyadenosine; Refractory/relapse;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：461 / 463

页数：2

共 28 条

[21] 2′-Chlorodeoxyadenosine (2-CdA) as Salvage Therapy for Langerhans Cell Histiocytosis (LCH). Results of the LCH-S-98 Protocol of the Histiocyte Society
Weitzman, Sheila
Braier, Jorge
Donadieu, Jean
Egeler, R. Maarten
Grois, Nicole
Ladisch, Stephan
Poetschger, Ulrike
Webb, David
Whitlock, James
Arceci, Robert J.
PEDIATRIC BLOOD & CANCER, 2009, 53 (07) : 1271 - 1276
[22] Anti TNF- therapy in patients with relapsed and refractory Langerhans cell histiocytosis: a phase II study
Legarreta, Alejandra Flores
Eckstein, Olive
Burke, Thomas M.
McClain, Kenneth L.
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2018, 35 (5-6) : 362 - 368
[23] Phase II Study of Cladribine (2-Chlorodeoxyadenosine) in Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma
Kensei Tobinai
Naokuni Uike
Yoshio Saburi
Takaaki Chou
Tetsuya Etoh
Masato Masuda
Fumio Kawano
Masao Matsuoka
Hirokuni Taguchi
Torahiko Makino
Yoshinobu Asano
Kazuo Tamura
Yasuo Ohashi
International Journal of Hematology, 2003, 77 : 512 - 517
[24] Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma
Tobinai, K
Uike, N
Saburi, Y
Chou, T
Etoh, T
Masuda, M
Kawano, F
Matsuoka, M
Taguchi, H
Makino, T
Asano, Y
Tamura, K
Ohashi, Y
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2003, 77 (05) : 512 - 517
[25] Langerhans cell histiocytosis with central nervous system involvement-complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib
Baumann, Michael
Cerny, Thomas
Sommacal, Andreas
Koeberle, Dieter
HEMATOLOGICAL ONCOLOGY, 2012, 30 (02) : 101 - 104
[26] Clofarabine Salvage Therapy in Refractory Multifocal Histiocytic Disorders, Including Langerhans Cell Histiocytosis, Juvenile Xanthogranuloma and Rosai-Dorfman Disease
Simko, Stephen J.
Tran, Huy D.
Jones, Jeremy
Bilgi, Mrinalini
Beaupin, Lynda Kwon
Coulter, Don
Garrington, Timothy
McCavit, Timothy L.
Moore, Colin
Rivera-Ortegon, Francisco
Shaffer, Linda
Stork, Linda
Turcotte, Lucie
Welsh, Esperanza C.
Hicks, M. John
McClain, Kenneth L.
Allen, Carl E.
PEDIATRIC BLOOD & CANCER, 2014, 61 (03) : 479 - 487
[27] Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study
Akira Morimoto
Yoko Shioda
Toshihiko Imamura
Kazuko Kudo
Toshiyuki Kitoh
Hiroshi Kawaguchi
Hiroaki Goto
Yoshiyuki Kosaka
Yukiko Tsunematsu
Shinsaku Imashuku
International Journal of Hematology, 2018, 108 : 192 - 198
[28] Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study
Morimoto, Akira
Shioda, Yoko
Imamura, Toshihiko
Kudo, Kazuko
Kitoh, Toshiyuki
Kawaguchi, Hiroshi
Goto, Hiroaki
Kosaka, Yoshiyuki
Tsunematsu, Yukiko
Imashuku, Shinsaku
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 108 (02) : 192 - 198

← 1 2 3 →